Navigation Links
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
Date:4/9/2009

ngs from the pre-clinical studies for the EV 71 vaccine were recently presented at the Chinese New Vaccines Reporting Conference. Sinovac is on track to file a clinical trial application with China SFDA in the third quarter of 2009. The Company holds the development rights to this first-of-its-kind vaccine and intends to submit the patent application for this vaccine in China in 2009. According to the March 27, 2009 report issued by China's Ministry of Public Health, there were 41846 cases of hand, foot, and mouth disease were reported in China from January 1, 2009 through mid-day on March 26, 2009, among which 94 of which were severe cases. The reported cases are mainly from young children under 5 years old (93.96% of total reported cases). Among the confirmed cased after testing in laboratory, 75% of the cases are caused by EV71. Additionally, hand, food and mouth disease incidence has been reported in both developed countries and developing countries in the past, indicating that it is a worldwide disease. Given the current severity of the hand, foot and mouth disease outbreak in China and other countries, Sinovac expects this new vaccine to become another flagship product in the future.

Sinovac is processing the clinical application to import and commercialize LG Life Sciences' hepatitis B vaccine, Euvax-B(TM), pursuant to the previously disclosed exclusive distribution agreement. Sinovac expects to obtain approval from the SFDA to conduct clinical trials in China in 2009 and intends leverage its established sales and marketing organization to distribute Euvax- B in China.

2009 Guidance

For the full year 2009, the Company expects sales of $55 million to $60 million, an increase of about 20% over 2008 sales. The 2009 sales growth rate assumes that (1) Healive will continue to generate a significant portion of Sinovac's sales revenue. Sinovac expects to maintain its leading position in the pr
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
2. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
3. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
4. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
5. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
6. Sinovac Releases Statement on Healive Vaccine Suspension
7. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
8. Sinovac Named to Deloitte Technology Fast 50 China
9. Sinovac to Participate in Two Upcoming Investor Conferences
10. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
11. Sinovac Biotech Holds 2007 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 long-travel ... for measuring displacement in rubber and other soft ... distance, the DSES-1000 can measure elongations up to ... mm. In addition, it achieves +/- 0.2 percent ... +/- 100 µm below 50-mm stroke. , The ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  RegeneRx ... today announced that it has received a Canadian ... by Actin-Sequestering Peptides.  This patent includes claims using ... numerous other actin-sequestering peptides for these purposes.  The ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
(Date:9/30/2014)... 30, 2014 The custom stainless steel ... Product Show 2014. The Boston Area Chapter of ISPE ... annual, day-long event for Wed., Oct. 1 at Gillette ... be the largest in ISPE Boston’s long history, with ... 3,000 attendees expected. , HOLLOWAY AMERICA President David ...
Breaking Biology Technology:Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... Antipsychotic Agent with Less Potential for ... and Metabolic Risks, SAN DIEGO, July 29 ... the United States Patent and,Trademark Office (USPTO) issued a ... broad coverage for a pharmaceutical,composition of zonisamide in combination ...
... up to 50% sucrose reduction while maintaining the sweet taste ... ... July 29, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), a leading ... ingredients for the food, beverage,and ingredient supply industries, announced today that ...
... July 29 Zenobia Therapeutics, Inc.,(Zenobia) announced ... Development,Initiative award from The Michael J. Fox ... research with potential to,fundamentally alter the course ... Dr. Christopher Ross of Johns Hopkins University,Zenobia ...
Cached Biology Technology:OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 2SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 3SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 4Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2
(Date:9/29/2014)... Between 1970 and 2010 populations of mammals, birds, ... 52 percent, says the 2014 Living Planet Report ... biodiversity loss occurs disproportionately in low-income countriesand correlates ... , In addition to the precipitous decline in ... warning signs about the overall health of the ...
(Date:9/29/2014)... world,s needs to make cheaper and more effective ... efficient catalytic materials and processes must be developed. ... State University, is tackling this problem with the ... Science Foundation. , The nearly $1.5 million project, ... Cascade Reactions," was to Eranda Nikolla, Ph.D., assistant ...
(Date:9/29/2014)... Ill. University of Illinois scientists have found compounds ... found them in a pretty unlikely placethe crushed seeds ... in jet fuel. , "The bioactive compounds in ... Pleasure, are a mixture of phytochemicals that work ... seed meal is a promising nutritional supplement because its ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2Wayne State research aims to develop new, more efficient catalytic materials 2New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2
... director of Syracuse Biomaterials Institute (SBI) and Milton and ... Syracuse University,s L.C. Smith College of Engineering and Computer ... functionally graded materials (FGMs) to shape memory polymers (SMPs). ... switch between two shapes, from a fixed (temporary) shape ...
... SPRING HARBOR, N.Y. (Jan. 5, 2011) Auxin is a ... aspects of plant development and physiology. A new book, ... overview of auxin and its many roles in plant biology. ... plant research," write the editors, Mark Estelle, Dolf Weijers, Karin Ljung, ...
... Treating fractures in children requires special knowledge of ... and adolescent patients is less often caused by technical ... in this age group. Using the example of treating ... Marburg-Gieen University Medical Center, and Lucas Wessel, University Medical ...
Cached Biology News:Syracuse University team develops functionally graded shape memory polymers 2
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... Application: A cleaning agent for ... surfaces, countertops, and pipettors. ... eliminating RNase contamination from microcentrifuge ... reactions. ,RNase Zap (R) ...
Mol wt: average mol wt12,360.96 Da by calculation...
... is part of a series of media originally ... Weiss et al. for the large scale propagation ... medium is primarily used for the growth and ... the propagation of viruses in these cell lines. ...
Biology Products: